| Ms Emily Ann Mikeman, MOTR/L | |
|
5500 N Western Ave Ste 153, Oklahoma City, OK 73118-4025 | |
| (405) 286-3749 | |
| (866) 435-3297 |
| Full Name | Ms Emily Ann Mikeman |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 5500 N Western Ave Ste 153, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265746531 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 1658 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Emily Ann Mikeman, MOTR/L 5500 N Western Ave Ste 153, Oklahoma City, OK 73118-4025 Ph: (405) 286-3749 | Ms Emily Ann Mikeman, MOTR/L 5500 N Western Ave Ste 153, Oklahoma City, OK 73118-4025 Ph: (405) 286-3749 |
News Archive
Echoing recent FDA warnings, a research group from Northern Ireland cautions against over-aggressive use of a group of drugs called "erythropoiesis-stimulating agents" (ESAs) to treat anemia in some cancer patients, according to a commentary in the April issue of The Oncologist, published by AlphaMed Press.
"Atherosclerosis is the leading cause of cardiovascular disease and the leading killer in Europe," said Professor Patrizio Lancellotti, President-Elect of the EACVI and Chairman of the EUROECHO Scientific Programme Committee. "Many of these deaths could be averted by diagnosis at a preclinical stage or early after the onset of symptoms."
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that it closed a €100 million placement of Preferred Stock to a group of investors.
The Centers for Disease Control and Prevention (CDC) today implemented a new system for providing travelers with guidance about potential health hazards and the steps they can take to protect themselves when traveling abroad. The new system makes it easier for the public to understand what their risks may be during an emerging public health crisis and what they can do to protect themselves.
Genoscience Pharma, a company focused on discovering and developing small molecules to treat cancer by targeting cancer stem cells, today announces that it will present data on its most promising candidate at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain, on November 18-21, 2014.
› Verified 4 days ago
Jovan Pride, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5701 Se 74th St Ste G, Oklahoma City, OK 73135 Phone: 405-610-1909 Fax: 405-610-1910 | |
Tung Le, MOTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3327 Nw 50th St, Oklahoma City, OK 73112 Phone: 405-946-7300 | |
Dr. Rachele Quinones, OTD, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6525 N Meridian Ave, Ste, Oklahoma City, OK 73116 Phone: 405-721-1115 | |
Keli A Boone, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1404 Nw 122nd St, Oklahoma City, OK 73114 Phone: 405-749-8131 | |
Caroline Jean Grubbs, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6400 N Santa Fe Ave, Suite B, Oklahoma City, OK 73116 Phone: 405-840-2903 Fax: 405-840-3256 | |
Ms. Denise Lashaun Shaw, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2828 Nw 57th St Ste 302, Oklahoma City, OK 73112 Phone: 405-840-1253 | |
Kallie Kim, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4220 Se 34th St, Oklahoma City, OK 73165 Phone: 785-213-1894 |